Michael Nedelcovych
Stock Analyst at TD Cowen
(1.57)
# 3,579
Out of 4,707 analysts
90
Total ratings
48.5%
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Michael Nedelcovych
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPRX Royalty Pharma | Rated: Buy | $65 → $68 | $60.59 | +12.23% | 11 | Sep 8, 2026 | |
| TSX: APTX Apotex Health Corp. | Initiated Coverage: Buy | $40.00 | $33.63 | +18.94% | 1 | Jul 6, 2026 | |
| NVO Novo Nordisk | Maintained: Hold | $42 | $45.16 | -7.00% | 31 | Jun 29, 2026 | |
| TAK Takeda Pharmaceutical Company | Maintained: Buy | $21 | $18.32 | +14.63% | 14 | Jun 4, 2026 | |
| JNJ Johnson & Johnson | Maintained: Buy | $250 | $269.12 | -7.10% | 2 | May 29, 2026 | |
| CHRS Coherus Oncology | Maintained: Buy | n/a | $1.37 | - | 13 | May 28, 2026 | |
| TSX: BHC Bausch Health Companies Inc. | Maintained: Hold | $9.66 | $8.86 | +9.03% | 9 | Apr 30, 2026 | |
| SWX: MOLN Molecular Partners AG | Maintained: Buy | CHF 15.00 | CHF 3.42 | +338.60% | 6 | Mar 16, 2026 | |
| TYO: 4502 Takeda Pharmaceutical Company Limited | Maintained: Buy | ¥5,135 | ¥5,760 | n/a | 1 | May 21, 2025 | |
| MOLN Molecular Partners AG | Maintained: Buy | $17 | $4.35 | n/a | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | ¥6,550 | ¥2,751 | n/a | 1 | Sep 9, 2024 |
Royalty Pharma
Sep 8, 2026
Rated: Buy
Price Target: $65 → $68
Current: $60.59
Upside: +12.23%
Apotex Health Corp.
Jul 6, 2026
Initiated Coverage: Buy
Price Target: $40.00
Current: $33.63
Upside: +18.94%
Novo Nordisk
Jun 29, 2026
Maintained: Hold
Price Target: $42
Current: $45.16
Upside: -7.00%
Takeda Pharmaceutical Company
Jun 4, 2026
Maintained: Buy
Price Target: $21
Current: $18.32
Upside: +14.63%
Johnson & Johnson
May 29, 2026
Maintained: Buy
Price Target: $250
Current: $269.12
Upside: -7.10%
Coherus Oncology
May 28, 2026
Maintained: Buy
Price Target: n/a
Current: $1.37
Upside: -
Bausch Health Companies Inc.
Apr 30, 2026
Maintained: Hold
Price Target: $9.66
Current: $8.86
Upside: +9.03%
Molecular Partners AG
Mar 16, 2026
Maintained: Buy
Price Target: CHF 15.00
Current: CHF 3.42
Upside: +338.60%
Takeda Pharmaceutical Company Limited
May 21, 2025
Maintained: Buy
Price Target: ¥5,135
Current: ¥5,760
Upside: n/a
Molecular Partners AG
Mar 14, 2025
Maintained: Buy
Price Target: $17
Current: $4.35
Upside: n/a
Sep 9, 2024
Maintained: Buy
Price Target: ¥6,550
Current: ¥2,751
Upside: n/a